Ciprofloxacin/dexamethasone

Drug Profile

Ciprofloxacin/dexamethasone

Alternative Names: 0.3% Ciprofloxacin/0.1% dexamethasone; CiloDex; CiloDex otic solution - Alcon; CiproDex Ophthalmic; CiproDex Otic; CiproDex Sterile Otic Suspension; Ciprofloxacin/dexamethasone otic suspension; Dexamethasone/ciprofloxacin

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer
  • Developer Alcon; Bayer
  • Class Anti-inflammatories; Fluorinated steroids; Fluoroquinolones; Glucocorticoids
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase inhibitors; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Otitis externa; Otitis media
  • Discontinued Eye disorders

Most Recent Events

  • 08 Apr 2011 Novartis completes acquisition of Alcon
  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer HealthCare Pharmaceuticals
  • 26 Aug 2010 Alcon has been acquired by Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top